BioCentury | Feb 17, 2021
Product Development

Start-up trends, COVID variants and J&J’s adcomm: a BioCentury podcast

...holds in shaping public opinion on COVID-19 vaccines. Associate Editor Virginia Li highlights newcos Ensoma and Quell Therapeutics Ltd....
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability. On Thursday, Quell Therapeutics Ltd.’s...
...UCL Technology FundCEO: Iain McGillPatents: None issuedTARGETSHLA-A2 – Major histocompatibility complex class I A 2 Stephen Hansen QEL-001 Quell Therapeutics Ltd. Syncona...
BioCentury | Jan 26, 2021
Emerging Company Profile

Resolution: Fighting fibrosis with macrophages

...Neogene Therapeutics Inc., regulatory T cell company Quell Therapeutics Ltd....
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...University; and an investigator at the Howard Hughes Medical Institute. Regulatory T cell therapy company Quell Therapeutics Ltd....
...officer of OliX Pharmaceuticals Inc. (KOSDAQ:226950). Targets CRAC - Calcium release-activated calcium channel Robin Sawka, BioCentury Staff Quell Therapeutics Ltd. American...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

...Ts. Targets FOXP3 - Forkhead box P3 IL-2 - Interleukin-2 Lauren Martz, Senior Editor Kyverna Therapeutics Inc. Sonoma Biotherapeutics Quell Therapeutics Ltd. AutoImmune...
BioCentury | Jun 27, 2019
Financial News

Syncona reaps tenfold return from Blue Earth exit

...pace of launching two or three start-ups each year. Although the firm's recent launch of Quell Therapeutics Ltd....
BioCentury | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...was global head of hematology and immunology business development at Shire plc. Treg cell company Quell Therapeutics Ltd....
...Staff Writer Xilio Therapeutics Inc. Amicus Therapeutics Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision BioSciences Inc. Quell Therapeutics Ltd. SymBio...
BioCentury | May 20, 2019
Financial News

Syncona launches Treg company Quell with £35 million A round

...round, with UCL Technology Fund providing the balance. Elisa Petris of Syncona Ltd. (LSE:SYNC) said Quell Therapeutics Ltd....
...additional financial terms. Mark Zipkin, Staff Writer Hannover Medical School King's College London Syncona Ltd. University College London Inflammation (unspecified) Autoimmune (unspecified) Transplant (unspecified) Quell Therapeutics Ltd. Tregs...
Items per page:
1 - 8 of 8
BioCentury | Feb 17, 2021
Product Development

Start-up trends, COVID variants and J&J’s adcomm: a BioCentury podcast

...holds in shaping public opinion on COVID-19 vaccines. Associate Editor Virginia Li highlights newcos Ensoma and Quell Therapeutics Ltd....
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability. On Thursday, Quell Therapeutics Ltd.’s...
...UCL Technology FundCEO: Iain McGillPatents: None issuedTARGETSHLA-A2 – Major histocompatibility complex class I A 2 Stephen Hansen QEL-001 Quell Therapeutics Ltd. Syncona...
BioCentury | Jan 26, 2021
Emerging Company Profile

Resolution: Fighting fibrosis with macrophages

...Neogene Therapeutics Inc., regulatory T cell company Quell Therapeutics Ltd....
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...University; and an investigator at the Howard Hughes Medical Institute. Regulatory T cell therapy company Quell Therapeutics Ltd....
...officer of OliX Pharmaceuticals Inc. (KOSDAQ:226950). Targets CRAC - Calcium release-activated calcium channel Robin Sawka, BioCentury Staff Quell Therapeutics Ltd. American...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

...Ts. Targets FOXP3 - Forkhead box P3 IL-2 - Interleukin-2 Lauren Martz, Senior Editor Kyverna Therapeutics Inc. Sonoma Biotherapeutics Quell Therapeutics Ltd. AutoImmune...
BioCentury | Jun 27, 2019
Financial News

Syncona reaps tenfold return from Blue Earth exit

...pace of launching two or three start-ups each year. Although the firm's recent launch of Quell Therapeutics Ltd....
BioCentury | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

...was global head of hematology and immunology business development at Shire plc. Treg cell company Quell Therapeutics Ltd....
...Staff Writer Xilio Therapeutics Inc. Amicus Therapeutics Inc. Lytix Biopharma A/S Mersana Therapeutics Inc. Oxford BioDynamics plc PMV Pharmaceuticals Inc. Precision BioSciences Inc. Quell Therapeutics Ltd. SymBio...
BioCentury | May 20, 2019
Financial News

Syncona launches Treg company Quell with £35 million A round

...round, with UCL Technology Fund providing the balance. Elisa Petris of Syncona Ltd. (LSE:SYNC) said Quell Therapeutics Ltd....
...additional financial terms. Mark Zipkin, Staff Writer Hannover Medical School King's College London Syncona Ltd. University College London Inflammation (unspecified) Autoimmune (unspecified) Transplant (unspecified) Quell Therapeutics Ltd. Tregs...
Items per page:
1 - 8 of 8